Cinnarizine, a blocker of slow calcium channels, is used in the treatment of cerebrovascular diseases, peripheral circulation disorders. In the prevention of migraine attacks and motion sickness.
Active ingredient: Cinnarizine 25 mg; Excipients: lactose monohydrate, wheat starch, povidone-K25 (polyvinylpyrrolidone K 25), colloidal silicon dioxide (Aerosil 200), talc, magnesium stearate
Indications / Application Notes
- Symptoms of cerebrovascular insufficiency (dizziness, tinnitus, headache, memory impairment, decreased concentration); - vestibular disorders (including Meniere's disease; dizziness, tinnitus, nystagmus, nausea and vomiting of labyrinth origin); - prevention of kinetoses ("road sickness" - sea and air sickness); - migraine (seizure prevention); - peripheral circulatory disorders: Raynaud’s disease, “intermittent” claudication, acrocyanosis, trophic disorders (including trophic and varicose ulcers)
Hypersensitivity to the drug, pregnancy, lactation. Lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome, childhood.
Mode of application
Inside, after a meal. With cerebrovascular insufficiency - 25 mg three times a day. In case of a violation of peripheral circulation - 50-75 mg three times a day. For vestibular disorders - 25 mg three times a day. The maximum daily dose should not exceed 225 mg (9 tablets) per day. The course of treatment is from several weeks to several months. In case of kinetosis ("road" disease) - 25 mg half an hour before the road (if necessary, repeat 25 mg after 6 hours).
Side effects
From the nervous system: drowsiness, fatigue, headache, extrapyramidal disorders (tremor of limbs and increase muscle tone, hypokinesia), depression. From the digestive system: dry mouth, pain in the epigastric region, dyspepsia, cholestatic jaundice. From the skin: sweating, lichen planus (extremely rare), skin rash. Other: allergic reactions, the development of lupus-like syndrome, a decrease in blood pressure, an increase in body weight.
Special instructions
Patients with Parkinson's disease should be prescribed only in cases where the benefits of its appointment exceed the possible risk of worsening. Due to the antihistamine effect, cinnarizine should be discontinued 4 days before an allergic skin test. Cinnarizine may affect the result of the anti-doping control of athletes (false positive). Patients with lactose intolerance should be aware that it is part of the drug. With prolonged use, a control laboratory study of the function of the liver, kidneys, and peripheral blood is recommended. The development of drowsiness is possible, especially at the beginning of treatment, therefore care should be taken when driving vehicles and engaging in other potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.
Release form
Tablets 25 mg. 50 tablets per blister of PVC / aluminum foil. 1 blister together with instructions for use are placed in a pack of cardboard
Storage conditions
Store in a dry, dark place, 15-25 °C. Keep out of the reach of children
Shelf life
3 years
PHARMA AD, Bulgaria